Deep Phenotyping of the Lipidomic Response in COVID and non-COVID Sepsis

Abstract

Lipids may influence cellular penetrance by pathogens and the immune response that they evoke. Here we find broad based lipidomic storm driven predominantly by secretory (s) phospholipase A2 (sPLA2) dependent eicosanoid production occurs in patients with sepsis of viral and bacterial origin and relates to disease severity in COVID-19. Elevations in the cyclooxygenase (COX) products of arachidonic acid (AA), PGD2 and PGI2, and the AA lipoxygenase (LOX) product, 12-HETE, and a reduction in the high abundance lipids, ChoE 18:3, LPC O-16:0 and PC-O-30:0 exhibit relative specificity for COVID-19 amongst such patients, correlate with the inflammatory response and link to disease severity. Linoleic acid (LA) binds directly to SARS-CoV-2 and both LA and its di-HOME products reflect disease severity in COVID-19. AA and LA metabolites and LPC-O-16:0 linked variably to the immune response. These studies yield prognostic biomarkers and therapeutic targets for patients with sepsis, including COVID-19. An interactive purpose built interactive network analysis tool was developed, allowing the community to interrogate connections across these multiomic data and generate novel hypotheses.

Prostanoids in Cardiac and Vascular Remodeling

“…Analysis of patients with sepsis revealed that although PGD 2 is elevated in patients with sepsis of bacterial or viral origin, it has a relative selectivity for sepsis induced by SARS-CoV-2. 226 Indeed, genetic deletion or pharmacological inhibition of DPr1 protects aged mice from lethal SARS-CoV-2 infection. 227…”